SPMS
MCID: SCN036
MIFTS: 45

Secondary Progressive Multiple Sclerosis (SPMS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 11 53 14 16 33
Multiple Sclerosis, Secondary Progressive 71
Multiple Sclerosis, Chronic Progressive 43
Chronic Progressive Multiple Sclerosis 16
Secondary-Progressive Ms 11
Spms 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0050783
MeSH 43 D020528
SNOMED-CT 68 425500002
ICD11 33 1045965709
UMLS 71 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology: 11 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary: Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to relapsing-remitting multiple sclerosis and multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are superpathway of L-citrulline metabolism and Amino acid metabolism. The drugs Dalfampridine and Cladribine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, brain and spinal cord, and related phenotypes are immune system and hematopoietic system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 relapsing-remitting multiple sclerosis 31.8 MOG MIR142 MBP IFNB1 ICOSLG CCR6
2 multiple sclerosis 31.5 NEFL MOG MIR155 MIR146A MIR142 MBP
3 primary progressive multiple sclerosis 30.7 SERPINA3 S100B NEFL MOG MIR146A MIR142
4 neuromyelitis optica 30.6 S100B NEFL MOG MBP CD40LG
5 autoimmune disease 30.5 MOG MIR146A MBP IL2RB IFNB1 ICOSLG
6 nutritional deficiency disease 30.5 SERPINA3 MBP CCR6
7 mild cognitive impairment 30.5 SERPINA3 NEFL MIR15B MIR142
8 chickenpox 30.5 MOG IFNB1 CCR6
9 hypersensitivity reaction type iii disease 30.5 SERPINA3 ICOSLG CCR6
10 myelitis 30.4 MOG MBP IFNB1 CCR6
11 rubella 30.4 MOG IFNB1 CD40LG
12 primary cutaneous t-cell non-hodgkin lymphoma 30.4 MIR155 IL2RB CCR6
13 progressive multifocal leukoencephalopathy 30.3 MOG MBP IFNB1 ICOSLG CCR6
14 common cold 30.3 IFNB1 ICOSLG CD40LG CCR6
15 sjogren syndrome 30.3 ICOSLG CD40LG CCR6
16 mental depression 30.3 SERPINA3 PRODH MIR155 MIR142 CCR6
17 viral infectious disease 30.2 SERPINA3 MIR155 IFNB1 ICOSLG CD40LG CCR6
18 alzheimer disease, familial, 1 29.8 SERPINA3 S100B PRODH NEFL MIR485 MIR15B
19 spinal cord disease 29.7 SERPINA3 MOG MIR485 MIR155 MIR142 MBP
20 demyelinating disease 29.6 SERPINA3 PRODH NEFL MOG MIR92A1 MIR15B
21 ectodermal dysplasia-syndactyly syndrome 1 11.0
22 neonatal hypoxic and ischemic brain injury 10.4 MBP ENO2
23 pineocytoma 10.4 S100B ENO2
24 congenital epulis 10.4 SERPINA3 ENO2
25 epulis 10.4 SERPINA3 ENO2
26 histiocytosis 10.4 SERPINA3 S100B CCR6
27 cutaneous fibrous histiocytoma 10.4 SERPINA3 S100B ENO2
28 amelanotic melanoma 10.4 SERPINA3 S100B ENO2
29 acute retrobulbar neuritis 10.4 MOG MBP IFNB1
30 balo concentric sclerosis 10.4 MOG MBP IFNB1
31 internuclear ophthalmoplegia 10.4 MOG MBP IFNB1
32 rhabdomyosarcoma 2 10.4
33 gastric squamous cell carcinoma 10.4 SERPINA3 CCR6
34 postinfectious encephalitis 10.4 MOG MBP
35 autoimmune optic neuritis 10.4 MOG MBP
36 granular cell tumor 10.4 SERPINA3 S100B ENO2
37 critical covid-19 10.4 SERPINA3 IFNB1 CCR6
38 partial optic atrophy 10.4 SERPINA3 MOG
39 paranoid schizophrenia 10.4 SERPINA3 S100B PRODH
40 tropical spastic paraparesis 10.4 MBP IL2RB IFNB1
41 post-vaccinal encephalitis 10.4 MBP CCR6
42 malignant granular cell myoblastoma 10.4 SERPINA3 ENO2
43 jejunoileitis 10.4 S100B CCR6
44 primary thrombocytopenia 10.4 ICOSLG CD40LG CCR6
45 bacterial sepsis 10.4 IFNB1 ICOSLG CCR6
46 herpangina 10.4 IFNB1 ICOSLG CCR6
47 immunoglobulin alpha deficiency 10.4 ICOSLG CD40LG CCR6
48 posterior uveitis 10.4 IL2RB ICOSLG CCR6
49 post-cardiac arrest syndrome 10.4 S100B ENO2
50 dysentery 10.4 SERPINA3 ENO2 CCR6

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.73 CCR6 CD40LG ICOSLG IFNB1 IL2RB MBP
2 hematopoietic system MP:0005397 9.44 CCR6 CD40LG ICOSLG IFNB1 IL2RB MBP

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalfampridine Approved Phase 4 504-24-5 1727
2
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
3 Potassium Channel Blockers Phase 4
4
Rituximab Approved Phase 2, Phase 3 174722-31-7
5
Carbamide peroxide Approved Phase 2, Phase 3 124-43-6
6
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
7
Chlorpheniramine Approved Phase 2, Phase 3 113-92-8, 132-22-9 2725
8
Cianidanol Approved, Withdrawn Phase 2, Phase 3 154-23-4 9064
9
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
10
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
11
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
12
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
13
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
14
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
15
Melphalan Approved Phase 3 148-82-3 4053 460612
16
Alemtuzumab Approved, Investigational Phase 3 216503-57-0
17
Carmustine Approved, Investigational Phase 3 154-93-8 2578
18
Etoposide Approved Phase 3 33419-42-0 36462
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
20
Lenograstim Approved, Investigational Phase 3 135968-09-1
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
24
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
25
Ofatumumab Approved Phase 3 679818-59-8
26
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
27
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
28
Simvastatin Approved Phase 3 79902-63-9 54454
29
Histamine Approved, Investigational Phase 3 51-45-6 774
30
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
31
Morphine Approved, Investigational Phase 3 57-27-2 5288826
32
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
33
Promethazine Approved, Investigational Phase 3 60-87-7 4927
34
Natalizumab Approved, Investigational Phase 3 189261-10-7
35
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 637568
36
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
37
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
39
Biotin Approved, Investigational, Nutraceutical Phase 3 58-85-5 253 171548
40
Epigallocatechin gallate Investigational Phase 2, Phase 3 989-51-5 65064
41
Epigallocatechin Experimental, Investigational Phase 2, Phase 3 970-74-1 72277
42
Epicatechin Investigational Phase 2, Phase 3 490-46-0 58571364 72276
43
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
44 Antirheumatic Agents Phase 2, Phase 3
45 Antineoplastic Agents, Immunological Phase 2, Phase 3
46 Liver Extracts Phase 2, Phase 3
47 Antioxidants Phase 2, Phase 3
48 Alkylating Agents Phase 3
49 Antineoplastic Agents, Alkylating Phase 3
50 Neuroprotective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod) Completed NCT04792567 Phase 4 BAF312;Baseline disease modifying therapies (DMTs)
2 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
3 An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
4 Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis Recruiting NCT04925557 Phase 4 Mayzent;Ocrevus
5 A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets Recruiting NCT04550455 Phase 4 Cladribine Tablets
6 A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714 Unknown status NCT03691077 Phase 3 Ocrelizumab
7 Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study Unknown status NCT02220933 Phase 3 MD1003 100mg capsule;Placebo
8 Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate Completed NCT03315923 Phase 2, Phase 3 Rituximab;Glatiramer Acetate
9 A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
10 A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
11 A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
12 A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Completed NCT01433497 Phase 3 Masitinib;Placebo
13 Lipoic Acid for Neuroprotection in Secondary Progressive MS Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
14 A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3 placebo;rituximab
15 Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
16 Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis Recruiting NCT04688788 Phase 3 Rituximab;Ocrelizumab;Fexofenadine;Paracetamol;Methylprednisolone
17 A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis Recruiting NCT04411641 Phase 3 Tolebrutinib;Placebo to match Tolebrutinib
18 A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) Recruiting NCT04047628 Phase 3
19 Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years Recruiting NCT03653273 Phase 3 DMT continuation
20 A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse Recruiting NCT05441488 Phase 3 Placebo;Masitinib (4.5)
21 ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function? Recruiting NCT04695080 Phase 2, Phase 3 Cladribine (MAVENCLAD®);Placebo
22 A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Recruiting NCT05232825 Phase 3 Ocrelizumab IV;Ocrelizumab SC;Methylprednisolone IV;Diphenhydramine IV;Dexamethasone given orally;Desloratadine given orally
23 A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Recruiting NCT04035005 Phase 3 Ocrelizumab;Placebo
24 A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) Recruiting NCT04458051 Phase 3 Tolebrutinib;Placebo
25 A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis. Recruiting NCT04544449 Phase 3 fenebrutinib;ocrelizumab;placebo
26 A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Recruiting NCT04548999 Phase 3 Ocrelizumab;Antihistamine;Methylprednisolone
27 A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Recruiting NCT02057159 Phase 2, Phase 3
28 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312. Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
29 A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability Active, not recruiting NCT03387670 Phase 3 Simvastatin;Placebo
30 An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis Active, not recruiting NCT02688985 Phase 3 Ocrelizumab;Methyloprednisolone;Antihistamine
31 An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis Active, not recruiting NCT03523858 Phase 3 Ocrelizumab
32 A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3 Ocrelizumab
33 A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
34 An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension Terminated NCT01416181 Phase 3 natalizumab;Placebo
36 A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
38 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis Terminated NCT00731692 Phase 3 FTY720;Placebo
39 Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study Terminated NCT02936037 Phase 3 MD1003 100mg capsule;PLACEBO
40 A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
41 A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage Unknown status NCT03896217 Phase 2 Simvastatin
42 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
43 A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition. Unknown status NCT01466114 Phase 2 estriol;Norethindrone
44 Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
45 Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2 Erythropoietin
46 Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) Unknown status NCT01815632 Phase 2
47 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
48 A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination Unknown status NCT02149706 Phase 2
49 A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
50 A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. Completed NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

Organs/tissues related to Secondary Progressive Multiple Sclerosis:

MalaCards : Bone Marrow, Brain, Spinal Cord, Bone, T Cells, Liver, Myeloid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 3534)
# Title Authors PMID Year
1
[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. 53 62
20443171 2010
2
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. 53 62
15645350 2004
3
Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. 53 62
9395124 1997
4
Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. 53 62
9343121 1997
5
Myelin basic protein gene polymorphism is not associated with chronic progressive multiple sclerosis. 53 62
7515903 1994
6
Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis. 53 62
7520286 1994
7
Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. 53 62
2056069 1991
8
Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility. 53 62
1985276 1991
9
Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. 62
36204852 2023
10
Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension. 62
36337053 2023
11
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. 62
36414428 2023
12
Multi-omics analysis of magnetically levitated plasma biomolecules. 62
36403493 2023
13
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. 62
36131595 2022
14
Density strips: visualisation of uncertainty in clinical data summaries and research findings. 62
34933930 2022
15
Specialized pro-resolvin mediators induce cell growth and improve wound repair in intestinal epithelial Caco-2 cell cultures. 62
36427427 2022
16
Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. 62
36454397 2022
17
Quantitative 7T sodium magnetic resonance imaging of the human brain using a 32-channel phased-array head coil: Application to patients with secondary progressive multiple sclerosis. 62
35892310 2022
18
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. 62
35971322 2022
19
Analysis and prediction of second primary malignancy in patients with breast cancer. 62
36381252 2022
20
The regulatory effect of specialized pro-resolving mediators on immune cells. 62
36411650 2022
21
Targeting inflammation and pro-resolving mediators with Anetholea anisita extract to improve scalp condition. 62
35979727 2022
22
Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis. 62
36470228 2022
23
Muscle architecture and its relationship with lower extremity muscle strength in multiple sclerosis. 62
34417688 2022
24
Associations between corpus callosum damage, clinical disability, and surface-based homologous inter-hemispheric connectivity in multiple sclerosis. 62
35536387 2022
25
Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization. 62
36362211 2022
26
Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study. 62
36084364 2022
27
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis? 62
36126539 2022
28
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis. 62
36336685 2022
29
Self-efficacy training as an adjunct to exercise in a person with progressive multiple sclerosis: a case report. 62
34081567 2022
30
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. 62
36229190 2022
31
Synchronous Second Primary Cancers of Hypopharyngeal Carcinoma in the Image-Enhanced Endoscopy Era. 62
36321782 2022
32
Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. 62
36420188 2022
33
Ginsenoside Rg1 promotes remyelination and functional recovery in demyelinating disease by enhancing oligodendrocyte precursor cells-mediated myelin repair. 62
35994846 2022
34
Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis. 62
35400704 2022
35
Psychological flexibility, distress, and quality of life in secondary progressive multiple sclerosis: A cross-sectional study. 62
36116384 2022
36
Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis. 62
36377669 2022
37
Working memory dysfunction differs between secondary progressive and relapsing multiple sclerosis: Effects of clinical phenotype, age, disease duration, and disability. 62
36436396 2022
38
Anti-inflammatory effects of siponimod on astrocytes. 62
35940437 2022
39
The nine hole peg test as an outcome measure in progressive MS trials. 62
36462470 2022
40
MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis. 62
36396446 2022
41
Inflammation and Infection in Pain and the Role of GPR37. 62
36430912 2022
42
Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. 62
36341839 2022
43
Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis. 62
36344261 2022
44
Limb apraxia in individuals with multiple sclerosis: Is there a role of semi-immersive virtual reality in treating the Cinderella of neuropsychology? 62
36417812 2022
45
miR-181a-5p is a potential candidate epigenetic biomarker in multiple sclerosis. 62
36103723 2022
46
Niclosamide targets the dynamic progression of macrophages for the resolution of endometriosis in a mouse model. 62
36369244 2022
47
Unraveling the genetics of polyamine metabolism in barley for senescence-related crop improvement. 62
36075308 2022
48
External validation of a clinical prediction model in multiple sclerosis. 62
36448727 2022
49
Toward Precision Phenotyping of Multiple Sclerosis. 62
36041861 2022
50
Novel pro-resolving lipid mediator mimetic 3-oxa-PD1n-3 DPA reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin-2 in mice. 62
36378290 2022

Variations for Secondary Progressive Multiple Sclerosis

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 SERPINA3 S100B MIR92A1 MIR485 MIR15B MIR146A
2 RISC complex GO:0016442 9.4 MIR92A1 MIR485 MIR15B MIR155 MIR146A MIR142

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polyamine metabolic process GO:0006595 9.46 SRM SMS
2 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR92A1 MIR15B MIR146A
3 positive regulation of metalloendopeptidase activity GO:1904685 9.13 MIR92A1 MBP
4 negative regulation of inflammatory response GO:0050728 8.92 MIR92A1 MIR15B MIR146A MIR142

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.35 MIR92A1 MIR15B MIR155 MIR146A MIR142
2 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR92A1 MIR485 MIR15B MIR155 MIR146A MIR142

Sources for Secondary Progressive Multiple Sclerosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....